(Q50989263)

26 March 2018

title

Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors. (English)

1 reference

26 March 2018

1 reference

8

Narikazu Boku

1 reference

26 March 2018

author name string

Masashi Niwakawa

1

1 reference

26 March 2018

Raizo Yamaguchi

2

1 reference

26 March 2018

Yusuke Onozawa

3

1 reference

26 March 2018

Hirofumi Yasui

4

1 reference

26 March 2018

Keisei Taku

5

1 reference

26 March 2018

Tateaki Naito

6

1 reference

26 March 2018

Shiro Akinaga

7

1 reference

26 March 2018

Nobuyuki Yamamoto

9

1 reference

26 March 2018

publication date

21 June 2013

1 reference

26 March 2018

published in

Cancer Science

1 reference

26 March 2018

volume

104

1 reference

26 March 2018

issue

8

1 reference

26 March 2018

page(s)

1039-1044

1 reference

26 March 2018

The biology of VEGF and its receptors

cites work

1 reference

Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications

21 January 2018

1 reference

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

21 January 2018

1 reference

Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors

21 January 2018

1 reference

Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma

21 January 2018

1 reference

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

21 January 2018

1 reference

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/CAS.12197

1 reference

26 March 2018

PMC publication ID

7657128

0 references

1 reference

26 March 2018